[1] Xu CH,Lin QS,Zhao YQ,et al.Clinical characteristics and risk factors of aeromonas bloodstream infections in patients with hematological diseases[J]. BMC Infect Dis,2022,22(1):13-15. [2] Al-Samkari H, Kolb-Sielecki J, Safina SZ,et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies:An international, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Haematol,2022,9(3):49-51. [3] 张盼盼,金皎,曾妮,等.血液病患儿医院感染的临床特点和病原学特征及药敏结果分析[J].贵州医科大学学报,2020,45(3):326-330,334. [4] Gokmen A, Şahin U, Soydan E,et al.315 - low dose tbi in addition to low dose melphalan and fludarabine as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with high risk hematologic malignancies[J]. Transplantat Cell Ther,2022,28(3S):193-194. [5] 程龙灿,杨婷,匡慧慧,等.热带地区恶性血液病患者血流感染特征及患者临床预后单中心分析[J].中国实验血液学杂志,2021,29(1):265-271. [6] Eissa S, Khedr R, Romeih M,et al.Clinical characteristics and outcome of invasive fungal sinusitis in children with hematological malignancies[J]. Med Mycol,2022,12(64):54-56. [7] 丁训杰. 实用血液病学[J]. 上海:上海医科大学出版社, 1992. [8] 张译心,李莹,温鲁平,等.恶性血液病并发肛周感染的临床特征及危险因素分析[J].中国肛肠病杂志,2021,41(12):24-25. [9] 张书芹,温红霞,于海涛,等.血液病合并毛霉菌感染患者的临床特征及预后分析[J].中国实验血液学杂志,2021,29(4):1340-1345. [10] Verlinden A, Jansens H, Goossens H,et al.Safety and efficacy of antibiotic de-escalation and discontinuation in high-risk hematological patients with febrile neutropenia:A single-center experience[J]. Open Forum Infect Dis,2022,9(3):394-395. [11] 罗文芳,陈中举,吴佳颖,等.血液病患者并发耐碳青霉烯肠杆科细菌血流感染临床特点及预后分析[J].内科急危重症杂志,2020,26(6):484-487. [12] 朱国庆,徐春晖,林青松,等.2014—2018年儿童恶性血液病患者中性粒细胞缺乏期血流感染病原学和临床特征分析[J].中华血液学杂志,2020,41(8):655-660. [13] 张鹏鹏,王丽娜,李明,等.恶性血液病粒细胞缺乏症患者医院感染的临床特征及危险因素分析[J].中国实验血液学杂志,2020,28(2):669-676. [14] Vasu S, Kromer M, Zhao M Q,et al.Utilizing organ-sparing marrow irradiation to condition patients prior to allogeneic hematopoietic cell transplant with high-risk hematologic malignancies: Results of a pilot study[J]. Transplantat Cell Ther,2022,28(3S):942-945. [15] 张颖,宋朝阳,李玉华,等.异基因造血干细胞移植治疗300例恶性血液病的疗效及患者预后的临床分析[J].中国实验血液学杂志,2019,27(6):1979-1985. [16] 郑湧智,乐少华,郑浩,等.儿童伯基特淋巴瘤/白血病35例临床特征及预后分析[J].中国实验血液学杂志,2019,27(4):1123-1130. [17] 陈彩,郑湧智,华雪玲,等.18例儿童系统性ALK阳性间变大细胞淋巴瘤的临床特征及患儿预后分析[J].中国实验血液学杂志,2019,27(3):809-815. [18] 邓倩,唐亦舒,成倩,等.恶性血液病患者革兰阳性菌血流感染的影响因素及预后分析[J].中华医院感染学杂志,2018,28(24):3771-3775,3803. [19] 凌兰兰. 造血干细胞移植治疗血液病临床疗效和预后分析[D].南京:南京医科大学,2017. [20] Vasudevan NR, Pasic I, Law AD,et al.Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma[J]. Eur J Haematol,2022,44(65):40-42. [21] 余正平,丁家华,陈宝安,等.不同供者来源异基因造血干细胞移植治疗恶性血液病69例疗效和预后分析[J].中国实用内科杂志,2012,32(11):862-864,897. [22] 王萌,董玉君,邱志祥,等.83例单倍体相合造血干细胞移植治疗恶性血液病的临床疗效及预后分析[J].中国实验血液学杂志,2016,24(3):833-839. |